After safety reviews, Oxford says there is insufficient evidence to say for certain that neurological symptoms developed by volunteers were or were not related to the vaccine.
AstraZeneca said clinical trials for the AstraZeneca Oxford Covid vaccine had resumed in UK following confirmation by the Medicines Health Regulatory Authority that trials were safe.
Oxford said the UK health regulator approved resuming the trials after review of the safety data triggered a pause on 6 September. It declined to disclose details about the participant’s illness.
AstraZeneca CEO Pascal Soriot sought to reassure investors after the Oxford vaccine trial was halted due to a person in the UK falling sick, triggering a review of safety data.
The AstraZeneca Plc paused the trial of its leading candidate, developed with Oxford University, to study a volunteer's illness. This pause shows the system is working as it should.
DCGI issued a show-cause notice to Serum Institute following reports that human trials of the Oxford vaccine were paused in UK after a candidate had an adverse reaction.
Suspension of the trial is a routine action whenever there is a potentially unexplained illness to ensure we maintain integrity of trials, AstraZeneca says.
The protocol will now be moved to DCGI V.G. Somani, who is likely to take a ‘decision by the end of the week’ given the urgency of the Covid challenge.
The real danger is not just discrimination, but that it hides behind a facade of objectivity. A recruiter can shrug: the system rejected the candidate.
FM adds that AI-assisted technologies should be adopted in all districts to bring development & highlights importance of collaborative ecosystems in tech innovation.
To be truly functional and durable, even eternal, a state doesn’t just need a leader, a party or an ideology. It needs functional and robust institutions.
COMMENTS